Solvonis Therapeutics (SVNS) Secures £1.3 Million to Propel SVN-001 Phase 3, SVN-002 IND, and SVN-015 NIDA Initiatives

Solvonis Therapeutics (SVNS) Secures £1.3 Million to Propel SVN-001 Phase 3, SVN-002 IND, and SVN-015 NIDA Initiatives →

Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical firm specialising in central nervous system disorders, has conditionally raised gross proceeds of £1.3 million through a placing of new ordinary shares announced…